Pd63-03 utility of Blue Light Flexible Cystoscopy for Bladder Cancer Surveillance After Intravesical Therapy

Abstract

INTRODUCTION AND OBJECTIVE:A second transurethral resection within 2 to 6 weeks after the initial resection (i.e. re-resection) is recommended for patients diagnosed with primary T1 bladder cancer as prior studies suggest therapeutic, diagnostic, and prognostic benefits. Results on survival endpoints, however, are sparse, conflicting, and often affected by various biases. Hence, we aimed to provide real-world evidence by investigating the survival benefit of reresection in T1 bladder cancer at the population level.METHODS: Retrospective population-wide observational cohort study based on pathology reports linked to health administrative data. We identified patients who were diagnosed with T1 bladder cancer in the province of Ontario (01/2001-12/2015) and used billing claims to ascertain whether they received re-resection within 2 to 10 weeks. The time-dependent effect of re-resection on survival outcomes was modeled by Cox proportional hazards regression (unadjusted and adjusted for numerous assumed patientand surgeon-level confounding variables). Effect measures were presented as hazard ratios and 95% confidence intervals.RESULTS: We identified 7,666 patients of which 2,162 (28.7%) underwent re-resection after a median time of 45 days (interquartile range: 35-56 days). The probability of dying from bladder cancer was consistently lower than the probability of dying from other causes (5 years: 15.8% versus 25.0%, 10 years: 18.7% versus 40.9%). Patients who received re-resection were less likely to die from any causes (0.68 [0.63-0.74], p<0.001) and from bladder cancer (0.66 [0.57-0.76], p<0.001) during any time of follow-up. After adjusting for all assumed confounding variables, re-resection was still significantly associated with a lower overall mortality (0.88 [0.81-0.95], p<0.001) while the association with cancer-specific survival marginally lost its statistical significance (0.87 [0.75-1.02], p[0.08).CONCLUSIONS: To the best of our knowledge, this populationwide study represents the largest cohort of patients diagnosed with T1 bladder cancer and provides real-world evidence supporting the utilization of re-resection in this group of patients.